Last reviewed · How we verify
Blast crisis of chronic myeloidleukemia
Approved treatments
- Daunorubicin Hydrochloride · Meiji Seika Pharma Co., Ltd
- Daunorubicine · Gruppo Italiano Malattie EMatologiche dell'Adulto
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Blast crisis of chronic myeloidleukemia patent landscape — cliff calendar, originator estates, attackable patents
- Blast crisis of chronic myeloidleukemia treatment landscape brief
- Blast crisis of chronic myeloidleukemia treatment updates RSS
Frequently asked questions about Blast crisis of chronic myeloidleukemia
What drugs treat Blast crisis of chronic myeloidleukemia?
Tracked treatments include Daunorubicin Hydrochloride, Daunorubicine.
What is the treatment for Blast crisis of chronic myeloidleukemia?
Standard treatment for Blast crisis of chronic myeloidleukemia includes Daunorubicin Hydrochloride, Daunorubicine. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Blast crisis of chronic myeloidleukemia patent cliff · Blast crisis of chronic myeloidleukemia CI report
- Treatment: Daunorubicin Hydrochloride · Meiji Seika Pharma Co., Ltd
- Treatment: Daunorubicine · Gruppo Italiano Malattie EMatologiche dell'Adulto
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing